AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$ARDX

Kelliher Mike sold $30K of ARDX

Kelliher Mike (Chief Business Officer) sold 7,758 shares of ARDELYX, INC. (ARDX) at $3.86 across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Kelliher Mike
Published Aug 25, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARDX
Bearish
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to affect ARDX's valuation significantly.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing that prompted the sale.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25 after market close

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$ARDXBearishHigh confidence
Context

Chief Business Officer sold 7,758 shares (~$30K) in a Form 4 filing.

Expected impact

Minimal downward pressure, likely <1% move.

Evidence & confidence

Sale size is modest relative to total holdings; insider remains a large shareholder.

Market effects

Sector

None; transaction is company‑specific.

Regional

None; ARDX trades on US markets only.

Global

Low; limited to ARDX shareholders.

Counterpoint

What could challenge this read

Insider may be diversifying without negative outlook; sale could be routine liquidity need.

Key entities

  • Officer
    Kelliher Mike

    Chief Business Officer of ARDELYX, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARDX insider trading history →

Related articles

AUG 14
$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

fool.com6 min
AUG 7
$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

investing.com4 min
AUG 6
$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow

SEC EDGAR 8-K5 min